JP2020505342A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020505342A5 JP2020505342A5 JP2019537357A JP2019537357A JP2020505342A5 JP 2020505342 A5 JP2020505342 A5 JP 2020505342A5 JP 2019537357 A JP2019537357 A JP 2019537357A JP 2019537357 A JP2019537357 A JP 2019537357A JP 2020505342 A5 JP2020505342 A5 JP 2020505342A5
- Authority
- JP
- Japan
- Prior art keywords
- agent
- antibody
- cells
- nrn1
- sema7a
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022139514A JP2022184862A (ja) | 2017-01-17 | 2022-09-01 | 腫瘍微小環境内の機能不全抗原特異的ｃｄ８＋ｔ細胞 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762447199P | 2017-01-17 | 2017-01-17 | |
| US62/447,199 | 2017-01-17 | ||
| PCT/US2018/014008 WO2018186924A1 (en) | 2017-01-17 | 2018-01-17 | Dysfunctional antigen-specific cd8+ t cells in the tumor microenvironment |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022139514A Division JP2022184862A (ja) | 2017-01-17 | 2022-09-01 | 腫瘍微小環境内の機能不全抗原特異的ｃｄ８＋ｔ細胞 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020505342A JP2020505342A (ja) | 2020-02-20 |
| JP2020505342A5 true JP2020505342A5 (enExample) | 2021-03-04 |
Family
ID=63712313
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019537357A Pending JP2020505342A (ja) | 2017-01-17 | 2018-01-17 | 腫瘍微小環境内の機能不全抗原特異的ｃｄ８＋ｔ細胞 |
| JP2022139514A Pending JP2022184862A (ja) | 2017-01-17 | 2022-09-01 | 腫瘍微小環境内の機能不全抗原特異的ｃｄ８＋ｔ細胞 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022139514A Pending JP2022184862A (ja) | 2017-01-17 | 2022-09-01 | 腫瘍微小環境内の機能不全抗原特異的ｃｄ８＋ｔ細胞 |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US11566077B2 (enExample) |
| EP (1) | EP3570887A4 (enExample) |
| JP (2) | JP2020505342A (enExample) |
| CN (1) | CN110740748A (enExample) |
| CA (1) | CA3049445A1 (enExample) |
| WO (1) | WO2018186924A1 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202436356A (zh) | 2016-10-11 | 2024-09-16 | 美商艾吉納斯公司 | 抗ｌａｇ－３抗體及其使用方法 |
| KR102629972B1 (ko) | 2017-04-13 | 2024-01-29 | 아게누스 인코포레이티드 | 항-cd137 항체 및 이의 사용 방법 |
| US20220023342A1 (en) * | 2018-11-30 | 2022-01-27 | Institut Gustave Roussy | Anti-neuropilin-1 and anti-programmed cell death-1 combination therapy for treating cancer |
| WO2020146772A1 (en) * | 2019-01-11 | 2020-07-16 | The Johns Hopkins University | Neuritin regulation of t cell anergy and t regulatory cell function |
| CN109913414A (zh) * | 2019-03-21 | 2019-06-21 | 吉林省银丰生物工程技术有限公司 | 肝癌afp特异性人工抗原递呈细胞诱导试剂盒 |
| US20210130438A1 (en) * | 2019-10-28 | 2021-05-06 | The Broad Institute, Inc. | Pan-cancer t cell exhaustion genes |
| CA3164578A1 (en) * | 2020-01-14 | 2021-07-22 | Scott KANNER | Compositions and methods for targeted protein stabilization by redirecting endogenous deubiquitinases |
| MX2022011409A (es) * | 2020-03-17 | 2022-12-02 | Ohio State Innovation Foundation | Vesiculas extracelulares de diseño para tratar la excitotoxicidad. |
| CN111781358A (zh) * | 2020-07-13 | 2020-10-16 | 张瑜 | Xab2蛋白作为卵巢癌预后和/或预测铂类耐药标志物 |
| CN112481375B (zh) * | 2020-08-27 | 2024-02-20 | 江苏大学 | 一种胃癌标志物及其应用 |
| CN114350616A (zh) * | 2022-01-24 | 2022-04-15 | 深圳市先康达生命科学有限公司 | 一种免疫细胞及其制备方法和应用 |
| CN114814231B (zh) * | 2022-03-08 | 2024-08-27 | 上海交通大学医学院附属瑞金医院 | 维甲酸诱导基因i在癌症治疗中的应用 |
| CN114561389A (zh) * | 2022-03-15 | 2022-05-31 | 南通市肿瘤医院 | Vrk1表达抑制剂及其应用 |
| CN115631857B (zh) * | 2022-04-01 | 2023-06-23 | 洛兮医疗科技(杭州)有限公司 | 甲状腺癌cd8+t细胞免疫相关基因预后预测模型 |
| CN114720691B (zh) * | 2022-05-10 | 2022-12-09 | 深圳粒影生物科技有限公司 | 一种检测生物标志物的试剂盒及其制备方法和应用 |
| CN115449548A (zh) * | 2022-09-20 | 2022-12-09 | 南京鼓楼医院 | Stac2卵丘细胞在评估卵母细胞受精能力中的应用 |
| CN116904309A (zh) * | 2023-05-26 | 2023-10-20 | 西安天隆科技有限公司 | 能平衡样本管接收部传热差异的模块、方法及pcr装置 |
| CN117192127B (zh) * | 2023-08-18 | 2024-06-14 | 肇庆医学高等专科学校 | 一种hcc治疗靶点的发现方法 |
| CN117590001A (zh) * | 2023-11-22 | 2024-02-23 | 厦门大学 | 外泌体tmem176b在制备诊断肿瘤的药物中的用途 |
| CN119120385B (zh) * | 2024-11-14 | 2025-03-14 | 四川大学华西医院 | 一种具有长效抑瘤效果的嵌合抗原受体t细胞及其制备方法和用途 |
| CN121046325B (zh) * | 2025-11-03 | 2026-03-17 | 杭州克斯珀基因技术有限公司 | 增强肿瘤微环境适应性的cep20敲除型til的制备方法及应用 |
| CN121114292B (zh) * | 2025-11-13 | 2026-01-23 | 合肥谱佳医学检验实验室有限公司 | 体外定量检测人血清中四种神经酰胺化合物的检测试剂盒 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA877772B (en) | 1986-10-23 | 1988-04-20 | Amoco Corporation | Target and background capture methods and apparatus for affinity assays |
| US20070072209A1 (en) | 2005-07-07 | 2007-03-29 | Ashlee Moses | Methods of treatment and diagnosis of Kaposi's sarcoma (KS) and KS related diseases |
| WO2008133641A2 (en) * | 2006-10-11 | 2008-11-06 | Curagen Corporation | Antibodies directed to gpnmb and uses thereof |
| US8637084B2 (en) * | 2009-07-14 | 2014-01-28 | Asahi Kasei Medical Co., Ltd. | Treatment method for epithelial cancerous organism |
| WO2011159877A2 (en) | 2010-06-18 | 2011-12-22 | The Brigham And Women's Hospital, Inc. | Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions |
| JP2012025694A (ja) * | 2010-07-23 | 2012-02-09 | Asahi Kasei Kuraray Medical Co Ltd | 癌治療剤 |
| CN103221428B (zh) * | 2010-09-09 | 2016-02-10 | 辉瑞公司 | 4-1bb结合分子 |
| US9297813B2 (en) * | 2010-11-11 | 2016-03-29 | Agency For Science, Technology And Research | Targeting metabolic enzymes in human cancer |
| EP2911669B1 (en) | 2012-10-26 | 2024-04-10 | The University of Chicago | Synergistic combination of immunologic inhibitors for the treatment of cancer |
| WO2014144666A2 (en) * | 2013-03-15 | 2014-09-18 | The University Of Chicago | Methods and compositions related to t-cell activity |
| EP3686219A1 (en) * | 2014-02-04 | 2020-07-29 | Pfizer Inc | Combination of a pd-1 antagonist and a 4-1bb agonist for treating cancer |
| CA2963935A1 (en) * | 2014-10-08 | 2016-04-14 | Novartis Ag | Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof |
| JP6647315B2 (ja) * | 2015-01-09 | 2020-02-14 | イーチュービクス コーポレイション | 組み合わせ免疫療法のための方法および組成物 |
| ES2986067T3 (es) * | 2015-12-17 | 2024-11-08 | Novartis Ag | Moléculas de anticuerpos frente a PD-1 y usos de las mismas |
| EP3471539A4 (en) | 2016-06-03 | 2020-02-26 | The Brigham and Women's Hospital | KLRG1 SIGNALING THERAPY |
-
2018
- 2018-01-17 JP JP2019537357A patent/JP2020505342A/ja active Pending
- 2018-01-17 CA CA3049445A patent/CA3049445A1/en active Pending
- 2018-01-17 CN CN201880016246.4A patent/CN110740748A/zh active Pending
- 2018-01-17 EP EP18780614.6A patent/EP3570887A4/en active Pending
- 2018-01-17 WO PCT/US2018/014008 patent/WO2018186924A1/en not_active Ceased
- 2018-01-17 US US16/476,219 patent/US11566077B2/en active Active
-
2022
- 2022-09-01 JP JP2022139514A patent/JP2022184862A/ja active Pending
-
2023
- 2023-01-06 US US18/151,112 patent/US20230416389A1/en not_active Abandoned
-
2024
- 2024-09-13 US US18/885,340 patent/US20250011452A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020505342A5 (enExample) | ||
| Sharma et al. | Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy | |
| CN113286811B (zh) | 改善过继性细胞疗法的效力和安全性 | |
| CN110475571B (zh) | 细胞免疫疗法前细胞毒性预调理的替代 | |
| Prieto et al. | Immunological landscape and immunotherapy of hepatocellular carcinoma | |
| Aris et al. | Combining immunotherapy with oncogene-targeted therapy: a new road for melanoma treatment | |
| JP2025013518A (ja) | Ｃａｒの抗腫瘍活性のための毒性管理 | |
| Patel et al. | Agonist anti-GITR monoclonal antibody and stereotactic radiation induce immune-mediated survival advantage in murine intracranial glioma | |
| Park et al. | Immune therapeutics in the treatment of advanced gastric and esophageal cancer | |
| Cabo et al. | Trial watch: immunostimulatory monoclonal antibodies for oncological indications | |
| Hebb et al. | Administration of low-dose combination anti-CTLA4, anti-CD137, and anti-OX40 into murine tumor or proximal to the tumor draining lymph node induces systemic tumor regression | |
| CN108289912A (zh) | 具有提高的免疫力或免疫抑制性细胞因子抗性的免疫细胞及其用途 | |
| JP2017507936A5 (enExample) | ||
| JP2015508816A5 (enExample) | ||
| Niedbała et al. | Glioblastoma: pitfalls and opportunities of immunotherapeutic combinations | |
| JP2022523804A (ja) | がんの処置における増強された有効性のためのｉｌ－４／ｉｌ－１３経路阻害剤 | |
| CN112351795A (zh) | 采用抗癌药剂和以包含非典型hla-i及新抗原复合物为靶点的抗体的联合抗癌疗法 | |
| Zhang et al. | Current advances and challenges in CAR-T therapy for hematological and solid tumors | |
| US20230096897A1 (en) | Lymphocyte Population and Methods for Producing Same | |
| Shah et al. | Multiple myeloma, targeting B-cell maturation antigen with chimeric antigen receptor T-cells | |
| Mandalà et al. | Rational combination of cancer immunotherapy in melanoma | |
| Bose | Immune checkpoint blockers and ovarian cancer | |
| CN113316449A (zh) | 胍那苄作为免疫疗法的佐剂 | |
| US20240358829A1 (en) | Lymphocyte Population and Methods for Producing Same | |
| US20200222462A1 (en) | Methods of treatment using decitabine and a cd123-targeted therapy |